里程碑！标新生物分子胶管线GT929在中国完成I/IIa期临床研究首例患者入组

发布日期：2024-03-06 文章来源：标新生物

今日，标新生物（Gluetacs Therapeutics）GlueTacs^®平台开发的分子胶管线GT929在中国成功完成首例复发难治的非霍奇金淋巴瘤患者入组，开启剂量爬坡阶段的研究，该试验旨在评估GT929在患者中的安全性、耐受性、药代动力学特征及初步疗效。

GT929 I/IIa期临床试验启动会现场照片

PRESS RELEASEShanghai, China – 6 Mar. 2024Gluetacs Therapeutics Commences First Patient Dosing in First-In-Human Phase I/IIa Trial to Assess GT929

Today, Gluetacs Therapeutics, has reached a significant milestone with the enrollment of the first patient in the Phase I/IIa clinical trial evaluating GT929, a molecular glue degrader from the GlueTacs^® platform. GT929’s initiation in this trial marks a pivotal step in addressing the urgent medical needs of patients with relapsed or refractory Non-Hodgkin lymphoma in China. The trial, focusing on dose escalation, aims to evaluate GT929’s safety, tolerability, pharmacokinetic profile, and efficacy.